Envestnet Portfolio Solutions
CPRX

Envestnet Portfolio Solutions’s Catalyst Pharmaceutical CPRX Stock Holding History

Envestnet Portfolio Solutions’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$498K Sell
20,120
-184
-0.9% -$4.38K ﹤0.01% 906
2025
Q4 		$474K Sell
20,304
-176
-0.9% -$3.92K ﹤0.01% 1086
2025
Q3 		$403K Sell
20,480
-2,896
-12% -$59.6K ﹤0.01% 1112
2025
Q2 		$507K Buy
23,376
+14,686
+169% +$347K ﹤0.01% 1093
2025
Q1 		$211K Buy
+8,690
New +$196K ﹤0.01% 1482

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Envestnet Portfolio Solutions's CPRX Position: Q1 2026 in Review

Envestnet Portfolio Solutions reduced its Catalyst Pharmaceutical (CPRX) stake by 0.91% in Q1 2026, selling an estimated $4.38K and leaving 20,120 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

Envestnet Portfolio Solutions first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $507K in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Envestnet Portfolio Solutions held 20,120 shares of Catalyst Pharmaceutical worth $498K as of Q1 2026.
  • Envestnet Portfolio Solutions sold 184 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.38K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q1 2026, its #906 holding.
  • Envestnet Portfolio Solutions first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Envestnet Portfolio Solutions's Catalyst Pharmaceutical position peaked at $507K in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q1 2026, filed 29 Apr 2026.